-+ 0.00%
-+ 0.00%
-+ 0.00%

Fosun Pharma Starts Phase II Trial of FXR0906 for Hypertriglyceridemia in China

PUBT·11/16/2026 10:03:29
Listen to the news
Fosun Pharma Starts Phase II Trial of FXR0906 for Hypertriglyceridemia in China
  • Shanghai Fosun Pharma announced on November 16, 2026, that a subsidiary initiated a Phase II trial of FXR0906 for hypertriglyceridemia in mainland China.
  • The liver-targeted siRNA drug remains in clinical development and requires national regulatory clearance before launch.
  • Research and development investment totaled approximately RMB 80 million through October 2026, including licensing fees, on an unaudited basis.
  • The group holds exclusive development, manufacturing and commercialization rights in mainland China, Hong Kong and Macau.
  • As of November 16, 2026, no siRNA treatment for hypertriglyceridemia had received marketing authorization in mainland China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261116-12414332), on November 16, 2026, and is solely responsible for the information contained therein.